Rockstart Law School: Milestones in Early-Stage Funding
Setting up and running a startup requires knowledge of the industry that you are in. It also requires knowledge about finance, marketing, customer service, management, and legal matters. There is no way of knowing everything you need to know, which is why the network that supports you becomes a valuable tool and asset.
Rockstart Law School is a combination of blog posts by outside contributors and vlog posts by Rockstart’s very own legal counsels Els Metten and Lisette Schuilwerve. They will show the roadmap to the legal side of starting and running a startup company. Rockstart Law School focuses on the Dutch law system and is meant as a resource and gives you lessons learned and suggestions, but is not meant to be used in the place of legal advice. Always consult your lawyer, but we hope these series of posts will give you a greater understanding of the legal needs and points of attention that you may encounter during your startup journey.
In this blog we take a closer look at “milestones” in a Term Sheet from an entrepreneur’s perspective, in the early stages of a company. You can watch the vlog by Rockstart’s legal team vlog and read the accompanying text below!
Funding and milestones
As an entrepreneur, your goal is to create value—and your company is your vessel to do so. The long and winding road towards that goal requires resources: primarily money. Most likely you don’t have that money readily available yourself, so you’ll need to convince investors to give you money. And what do investors want? A decent return on investment, obviously. But they are also keen to mitigate their risks. Which is why investors may make their investment conditional on milestones.
In fundraising, you show investors your stellar plan of attack—also known as a business plan or pitchdeck. Your plan contains the goals and the estimated resources needed to reach them. Based on your own plans and forecasts, you now convince an investor to invest, say, EUR 600,000 in your company. However, let’s assume the investor proposes to structure the investment in tranches, based on the goals (milestones) you yourself outlined in your plan. The investor will in principle invest a total amount of EUR 600,000, but will only actually make that investment available in three tranches of EUR 200,000 each. Each tranche will be conditional upon reaching a milestone. The size of each tranche will be based on your own estimation of resources needed.
Should you accept the offer?
If you’re anxious to secure the funding—as a lot of entrepreneurs are—this may sound tempting. Accepting the offer means the deal gets done quicker, which means less risk for the investor. One way or another you need to give the investor some control over how the money is spent anyway. Tranche-based investing allows you to do so without extensive provisions on governance. Plus, you did your homework with the numbers, right? So what can possibly go wrong?
Well, quite a lot. Although we wouldn’t go as far as to advise you never to agree on tranche-investing based on milestones, we do advise you to be cautious.
Downsides of funding with milestones
Focus on milestone-seeking instead of long-term value-creation
You are locked-in with a short runway, which will only be extended if you reach the next milestone. Your company will therefore be inclined to focus on reaching milestones, to the point where this is not—or no longer—in the long-term interest of the company. Your focus should be on value-maximisation in the long-term and not milestone-seeking in the short-term.
Milestones limit flexibility
Things. Will. Turn. Out. Differently. Your stellar plan is usually outdated the moment it lands in the investor’s inbox. Along the way, you will need to continuously modify your plan of attack (pivot anyone?). Such modifications would lead to missing your milestones. This means re-negotiating with your investor in order to secure funding. This becomes far more difficult when you’re in a bad bargaining position and at a moment when time and energy is better spent on the business.
Milestones may encourage the concealment of setbacks
Because of your short runway, you may be tempted to obfuscate or conceal setbacks or change of plans in order to secure the next tranche, instead of building a long-term relationship based on trust.
Short runways scare off top talent
New (potential) elite team members will be aware of risk and will (or should) therefore ask you about your runway to assess whether (s)he should hop on board. You will have to admit that runway is short and conditional… and the potential team member will sign up with a competitor.
Milestones may lead to unfair outcomes
Last but not least: you are, in fact, allowing an investor to keep investing in your company at the initial valuation even though that valuation increasingly becomes off-the-mark when you progressively reach your milestones.
Having said that, we reiterate that tranche-investing based on milestones is not always a bad thing. If you do decide to accept milestones, or simply have no choice, keep in mind the following:
When negotiating funding with milestones
- Be sure that milestones are SMART: Specific, Measurable, Attainable, Relevant and Time-related. Milestones that are not
SMART are prone to leading to disagreements on whether they have been met. The investor generally has the upper hand here, the money you need badly is in his pocket, and you will need to go to court to force him to give it to you.
- So generally speaking, quantitative milestones such as financial metrics or (unique) users are to be preferred over qualitative milestones. The latter are, by their nature, more fuzzy/vague. Should you nonetheless consider qualitative milestones, we advise you to agree that you regularly evaluate if, and to what extent, they are met, and to have parties sign a document containing joint findings and action points in order to avoid surprises.
- To partially mitigate the downsides mentioned above, limit the amount of milestones and makesure that each tranche provides you with sufficient runway, allowing for change of plans and a margin of error. You don’t want to be on continuous life-support.
- Agree with the investor that you have the right but not the obligation to draw down another tranche if a milestone is met. In other words, if the investor is unwilling to provide you with all the money upfront, why should you be required to accept all that money upfront? If you can get a better deal along the way, you should be able to go for it.
Our preferred alternative
Find an investor who trusts you will spend his money wisely and who acknowledges that you shouldn’t put an entrepreneur on a leash too tight. Preferably, an investor who invests unconditionally upfront and only request a limited amount of control to protect their investment.
For example, if the investor invests in equity, we advise that you enter into a shareholders’ agreement, in which you agree that a limited number of decisions require the investor’s approval. If they invest in (convertible) debt, we advise that the loan agreement includes covenants with the same effect.
But obviously as an entrepreneur you don’t want to be hampered too much in working your entrepreneurial magic. So you definitely should (also) negotiate this carefully, ideally with the assistance of an expert.
Any questions and remarks? Drop us a line at email@example.com or firstname.lastname@example.org . (Graphics: copyright of De Roos Advocatuur – designed by our very own legal visuals specialist Maurits Fornier (email@example.com).)
Also on Rockstart
Rocking Writing and Content Generation with Rockstart Amsterdam August 22 2017 | David Chislett I spent most of my Thursday last week at Rockstart. They invited me in as a writing and content generation expert to spend 30 mins each with a few of their entrepreneurs. This is ...
Direct to Consumer Digital Medical Devices – A Cautionary Tale for Entrepreneurs August 17 2017 | Lisa Suennen Last week I had a startup entrepreneur come to me with an idea about how to “pivot” his company strategy. The company, which had begun as a medical device company but couldn...